Publications scientifiques sur le lymphome

Les résultats et les conclusions des travaux menés par l’écosystème Experts Recherche Lymphome sont publiés dans des journaux médicaux de premier plan.

Lysa 2025_Synthetic control arm from mixed clinical trials and real-world data from the LYSA group for untreated diffuse large B-cell lymphoma patients aged over 80 years: a bona fide strategy for innovative clinical trials.
Letailleur V, Chaillol I, Cherblanc F, Ghesquières H, Peyrade F, Guidez S, Bijou F, Sesques P, Rossi C, Fornecker L-M, Fouillet L, Carras S, Chartier L, Belot A, Oberic L, Jardin F, Tessoulin B.
Blood Cancer J 2025;15:190. En savoir plus
Lysa 2025_Invasive Fungal Infections after CD19 CAR T-cell Therapy for B-Cell Lymphoma: a LYSA study from the DESCAR-T Registry
Bouvier A, Durand A, Dupont V, Gower N, Castilla Lorente C, Campidelli A, Dulery R, Gangneux J-P, Joris M, Eloit M, Latiere C, di Blasi R, Denis B, Gabellier L, Morschhauser F, Casasnovas O, Houot R, Angebault C, Bachy E, Le Bras F, Gastinne T, Tudesq J-J, Lemonnier F, Melica G
Clin Microbiol Infect 2025:S1198-743X(25)00502-6. En savoir plus
Lysa 2025_Risk stratification of diffuse large B-cell lymphoma patients using plasma NMR-based metabolomics at diagnostic
Montagne A, Bertho G, Papastergiou T, Chartier L, Ricci R, Jardin F, Ghesquieres H, Rossi C, Morschhauser F, Haioun C, Ribrag V, Feugier P, Brisou G, Obéric L, Gaulard P, Giraud N, Bennani Y, Thieblemont C, Baud VI
Blood Adv 2025:bloodadvances.2025017248. En savoir plus
Lysa 2025_Outcome of Patients with Mantle Cell Lymphoma after Failure of Anti-CD19 CAR-T Cell Therapy: A Descar-T Study By Lysa Group
Aymard M, Cheminant M, Houot R, Cuozzo A, Gat E, Thieblemont C, Ricard L, Roulin L, Bouabdallah K, Safar V, Guidez S, Fayard A, Brisou G, Ysebaert L, Hermine O, Tessoulin B, Herbaux C, Le Gouill S, Sarkozy C.
Blood Adv 2025:bloodadvances.2025017234 En savoir plus
Lysa 2025_Poor Outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.
Cayla, S, Arnulf, B
Blood Advances 2025 En savoir plus
Lysa 2025_An Individualized Prediction Model for Early-Stage Classic Hodgkin’s Lymphoma.
Rodday AM, Evens AM, Maurer MJ, Upshaw JN, Counsell N, Rossetti S, Chang C, Cui Z, Xiang Q, Mwangi R, Advani R, Andre M, Gallamini A, Hay AE, Hodgson DC, Hoppe RT, Hutchings M, Johnson P, Mou E, Opat S, Raemaekers J, Savage KJ, Parsons SK, Radford J.
NEJM Evid 2025;4:EVIDoa2500115 En savoir plus
Lysa 2025_Anti-CD19 CAR T-cell therapy for patients with Richter transformation: A LYSA study from the DESCAR-T registry.
Bensaber H, Ferrant E, Duléry R, Beauvais D, Feugier P, Gastinne T, Villemagne B, Paubelle E, Castilla Llorente C, Roulin L, Longval T, Fayard A, Bay J-O, Le Gouill S, Gat E, de Antonio M, Morschhauser F, Guièze R.
Br J Haematol 2025;207:1143–7 En savoir plus
Lysa 2025_. Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment
Claudel A, Cottereau A-S, Bachy E, Itti E, Feugier P, Rossi C, Lemonnier F, Camus V, Daguindau N, Cartron G, Nicolas-Virelizier E, Mboumba D-L, Cardoso C, Bommier C, Tessoulin B, Fruchart C, Gilbert A, Durot E, Fleck E, Pica GM, Zerazhi H, Guidez S, Cheminant M, Sarkozy C, Xerri L, Vercellino L, Trabelsi N, Gomes L, Portugues C, Viailly P-J, Delfau-Larue M-H, Morschhauser F.
Blood 2025;146:913–25. En savoir plus
Lysa 2025_Immunoglobulin G Receptors (FcγR), in Addition to Target-Antigen and Neonatal Fc Receptor (FcRn), Influence Rituximab Pharmacokinetics.
Ternant D, Le Tilly O, Cartron G, Desvignes C, Bensalem A, Mulleman D, Bejan-Angoulvant T, Gouilleux-Gruart V, Paintaud G.
Clin Pharmacokinet 2025 En savoir plus
Lysa 2025_Impact of socioeconomic individual and ecological factors on extreme diagnosis-to-treatment interval in diffuse large B-Cell lymphoma in the French real-world cohort REALYSA.
Cantrelle C, Belot A, Monnereau A, Bijou F, Rossi C, Bommier C, Hafirassou HK, Fouillet L, Ghesquières H, Ysebaert L, Le Guyader Peyrou S.
Cancer Epidemiol 2025;98:102875 En savoir plus
Lysa 2025_Brentuximab Vedotin addition to Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphoma: a LYSA Phase II Study.
Tournilhac O, Bouabdallah K, Lecolant S, Hacini M, Laribi K, Bailly S, Belmondo T, Maerevoet MMF, Ysebaert L, Guidez S, Le Gouill S, Bonnet C, Andre M, Dupuis J, Thieblemont C, Bachy E, Daguindau N, Morschhauser F, Tricot S, Moulin C, Banos A, Houot R, Chauchet A, Gyan E, Cartron G, Farhat H, Camus V, Drenou B, Zerazhi H, Sibon D, Nicolas Virelizier E, Delette C, Snauwaert S, Bailly S, Delarue R, Carras S, Ledoux-Pilon A, Parrens M, Griolet S, Gaulard P, Delfau-Larue M-H, de Leval LL, Damaj GL.
Blood Adv 2025:bloodadvances.2024015787 En savoir plus
Lysa 2025_IRF4 promotes immune evasion and shapes the tumor microenvironment in Follicular Lymphoma
Dasari S, Wenzl K, Nelson GM, Contreras Guzman E, Wang Z, Chartier L, Yang Z-Z, Villasboas JC, Olson J, Mukherjee P, Bhardwaj V, Tang X, Negaard BJ, Zakrzewski JL, King RL, Huet S, Tesson B, Maurer MJ, Morschhauser F, Nowakowski GS, Adelman KL, Singh H, Pasqualucci L, Shlomchik M, Novak AJ, Ansell SM, Mondello P
Blood Cancer Discov 2025 En savoir plus
Lysa 2025_Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B-Cell Lymphoma.
Penichoux J, Decazes P, Rossi C, Sesques P, Haioun C, Durot E, Gower N, Willaume A, Oberic L, Paillassa J, Antier C, Renaud L, Tournilhac O, Thieblemont C, Besson C, Lebras L, Choquet S, Le Du K, Bonnet C, Bailly S, Damaj G, Laribi K, Houot R, Chauchet A, Becker S, Tonnelet D, Tilly H, Jardin F, Lévêque E, Camus V.
Hematol Oncol 2025;43:e70117 En savoir plus
Lysa 2025-Synthetic Control Arm from Clinical Trial and Real-World Cohorts from Lysa Group for Untreated Older Classical Hodgkin Lymphoma for Innovative Clinical Trial Designs.
Ghesquieres H, Claves F, Murairi T, Krzisch D, Guidez S, Cherblanc F, Pauc A, Bouabdallah K, Touati M, Le Bras F, Borel C, Bijou F, Fornecker LM, Delapierre B, Quittet P, Chartier L, Rossi C.
Hematological Oncology 2025;43:e371_70094. En savoir plus
Lysa 2025_Maximum tumor diameter is associated with relapse risk in limited-stage Hodgkin lymphoma: an international study
Phillips EH, Counsell N, Illidge T, Andre M, Aurer I, Fiaccadori V, Fortpied C, Neven A, Federico M, Barrington SF, Raemaekers J, Radford J.
Blood Adv 2025;9:2266–74 En savoir plus
Lysa 2025_TRANSCAR: Real-World outcomes of CD19CAR T Cell Therapy in relapsed/refractory transformed indolent lymphomas
Stephan P, Di Blasi R, Roulin L, Galtier J, Calvani J, Meignin V, Donzel M, Traverse-Glehen A, Poullot E, Parrens M-C, Dupont V, Marquet A, Le Gouill S, Houot R, Gros F-X, Lemonnier F, Bachy E, Thieblemont C, Sesques P
Blood Adv 2025:bloodadvances.2025015834 En savoir plus
Lysa 2025_Investigating the Association Between a Continuous Variable and a Time-To-Event Outcome: Going Beyond the Cut-Off Approach
Murairi Mirimo T, Portugues C, Remontet L, Chartier L, Cottereau A-S, Morland D, Morschhauser F, Fauvernier M, Belot A.
Hematol Oncol 2025;43:e70105. En savoir plus
Lysa Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non-Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group.
Herbaux C, Bachy E, Bouabdallah R, Guidez S, Casasnovas O, Feugier P, Damaj G, Tilly H, Ysebaert L, Le Gouill S, Morineau N, Gyan E, Gressin R, Houot R, Cheminant M, Morschhauser F, Thieblemont C, Haioun C, Nicolas-Virelizier E, Fornecker L-M, Daguindau N, Cartron G.
Br J Haematol 2025 En savoir plus
Lysa 2025_Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study
Sarkozy C, Chartier L, Ribrag V, Gressin R, Geisler CH, Kluin-Nelemans HC, Thieblemont C, Morschhauser F, Lemonnier F, Safar V, Tessoulin B, Oberic L, Damaj G, Ghesquières H, Bouabdallah K, Casasnovas RO, Houot R, Klapper W, Burroni B, Pott C, Delfau-Larue M-H, Macintyre E, Callanan M, Jerkeman M, Unterhalt M, Hoster E, Dreyling M, Le Gouill S, Hermine O, Cheminant M.
Blood Cancer J 2025;15:78 En savoir plus
Lysa 2025_Outcomes of patients with Hodgkin lymphoma receiving Brentuximab Vedotin (BV) as maintenance therapy after ASCT according to previous exposure to BV.
Martínez C, Khvedelidze I, Fekom M, Deau Fischer B, Marouf A, Ghesquières H, Fornecker L-M, Merli F, Stefani PM, Massaro F, Botto B, Ferhanoğlu B, Akay OM, Özbalak M, Espeso de Haro M, Romero S, Galimard J-E, Glass B, Bazarbachi A, Sureda A.
Bone Marrow Transplant En savoir plus
Lysa 2025_Are oldest old patients with diffuse large B-cell lymphoma different than their younger counterparts: Results from the REALYSA real-life cohort
Cantrelle, Christelle; Belot, Aurélien; Monnereau, Alain; Bijou, Fontanet; Rossi, Cédric; Khebbeb Hafirassou, Hadia; Fouillet, Ludovic; Soubeyran, Pierre; Ghesquières, Hervé; Ysebaert, Loic; Le Guyader Peyrou, Sandra; Galvin, Angéline
Cancer Epidemiol 2025;96:102812 En savoir plus
Lysa 2025_Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study
Cartron, Guillaume; Houot, Roch; Al Tabaa, Yassine; Le Bras, Fabien; Ysebaert, Loïc; Choquet, Sylvain; Jardin, Fabrice; Bay, Jacques-Olivier; Gros, François-Xavier; Morschhauser, Franck; Casasnovas, Olivier; Gastinne, Thomas; Thieblemont, Catherine; Joris, Magalie; Ricard, Laure; Regny, Caroline; Drieu La Rochelle, Laurianne; Feugier, Pierre; Marcais, Ambroise; Griolet, Samuel; Tarte, Karin; Laurent, Camille; Sesques, Pierre
Nat Cancer 2025;: En savoir plus
Lysa 2025_High-dose therapy followed by autologous stem cell transplantation emerges as the preferred salvage therapy in patients with limited-stage Hodgkin lymphoma progressing/relapsing after initial therapy: A subset analysis of the EORTC/LYSA/FIL H10 trial
Manuel, Gotti; Stepanishyna, Yana; Skrypets, Tetiana; Marcheselli, Luigi; Cristinelli, Caterina; Botto, Barbara; Tonino, Sanne; Cavalieri, Doriane; Pulsoni, Alessandro; Hutchings, Martin; Hammoud, Mohammad; Fortpied, Catherine; Rigacci, Luigi; Plattel, Wouter; André, Marc; Federico, Massimo
Hemasphere 2025;9:e70105 En savoir plus
Lysa 2025_Efficacy of tazemetostat in combination with R-CHOP in elderly patients newly diagnosed with diffuse large B cell lymphoma: results of the EpiRCHOP phase II study of the LYSA
Sarkozy, Clémentine; Molina, Thierry Jo; Dubois, Sydney; Portugues, Cédric; Bohers, Elodie; Ysebaert, Loic; Houot, Roch; Pica, Gian Matteo; Ruminy, Philippe; Herbaux, Charles; Gastinne, Thomas; Thieblemont, Catherine; Haioun, Corinne; Guidez, Stéphanie; Bonnet, Christophe; Crochet, Gilles; Veresezan, Liana; Choquet, Sylvain; Bachy, Emmanuel; Jardin, Fabrice; Morschhauser, Franck; Ribrag, Vincent
EClinicalMedicine 2025;82:103157 En savoir plus